208 results about "Serum protein albumin" patented technology

An optically clear, pharmaceutically acceptable aqueous composition comprising paclitaxel or a derivative thereof, serum albumin and a pharmaceutically acceptable vehicle, wherein the composition comprises no more than 10% organic solvent and has a pH of about 3.0 to about 4.8, is described. The serum albumin can be fatted or defatted, and the composition can optionally be lyophilized or optionally lyophilized and reconstituted. At least 70% of the paclitaxel is bound to serum albumin, the ratio of paclitaxel to albumin is at least about 1:5, and the concentration of paclitaxel is at least about 25 μg/ml. Methods of making and using this composition an also provided.

Production of recombinant human serum albumin with rice albuminous cell as biological reactor is carried out by taking rice albuminous cell protein as storage site for recombinant protein, taking rice albuminous specific expression starter and signal peptide, entering inductive recombinant human serum albumin into inner-film system of rice serum albumin cell and storing it in rice albuminous protein. It is cheap, has more yield and higher expression.

The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (¹⁰Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding ¹⁰Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.

A method of propagating mammalian endodermally derived progenitors such as hepatic progenitors, their progeny, or mixtures thereof is developed which includes culturing mammalian progenitors, their progeny, or mixtures thereof on a layer of embryonic mammalian feeder cells in a culture medium. The culture medium can be supplemented with one or more hormones and other growth agents. These hormones and other growth agents can include insulin, dexamethasone, transferrin, nicotinamide, serum albumin, beta-mercaptoethanol, free fatty acid, glutamine, CUSO4, and H2SeO3. The culture medium can also include antibiotics. Importantly, the culture medium does not include serum. The invention includes means of inducing the differentiation of the progenitors to their adult fates such as the differentiation of hepatic progenitor cells to hepatocytes or biliary cells by adding, or excluding epidermal growth factor, respectively. The method of producing mammalian progenitors is useful in that the progenitors can be used subsequently in one or more of the following processes: identification of growth and differentiation factors, toxicological studies, drug development, antimicrobial studies, or the preparation of an extracorporeal organ such as a bioartificial liver.

The present invention provides compositions that contain botulinum toxin and a hyaluronidase, and that lack human or recombinant serum albumin. The present invention also provides methods of administering the pharmaceutical composition to a subject in need thereof.

Compositions and methods for isolating and expanding human mesenchymal stem/progenitor cells through multiple passages in defined serum-free environments are provided. The culture media compositions includes a basal medium supplemented with a nutrient mixture such as Ham's F12 nutrient mixture, glutamine, buffer solutions such as sodium bicarbonate and hepes, serum albumin, a lipid mixture, insulin, transferrin, putrescine, progesterone, fetuin, hydrocortisone, ascorbic acid or its analogues such as ascorbic acid-2-phosphate, fibroblast growth factor and transforming growth factor β, and are free of serum or other undefined serum substitutes such as platelet lysate. Methods employing these compositions and protein-coated surfaces for the isolation of mesenchymal stem/progenitor cells from human bone marrow and other tissues such as adipose tissue are also provided. Finally, methods are also provided for serially expanding these cells through multiple passages without losing mesenchymal stem cell-specific proliferative, phenotypical and differentiation characteristics.

The present invention provides methods of treatment of patients suffering from the complications of blood sugar disorders: diabetic peripheral neuropathy and diabetic nephropathy by administration of IGF-1 via protein therapy or gene therapy. It relates to methods of treating an individual having a diabetic disorder or a hyperglycemic disorder, comprising administering to the individual an effective amount of a DNA vector expressing IGF-1Eb or IGF-1Ec in vivo or an effective amount of at the IGF-1Eb or IGF-1Ec protein in the early hyperalgesia stage or in patients that have advanced to the hyposensitivity stage. Treatment at the early hyperalgesia stage prevents subsequent hyposensitivity with increases or maintenance of sensory nerve function. IGF-1Eb or IGF-1Ec treatment also increases muscle mass and improves overall mobility, which indicates a treatment-related improvement in motor function. Treatment with IGF-1Eb or IGF-1Ec at the hyposensitivity stage reverses hyposensitivity and improves muscle mass and overall health. Systemic IGF-1 provides a therapeutic modality for treating hyposensitivity associated with DPN. In addition, IGF-1Eb or IGF-1Ec provides a therapeutic modality for treating diabetic nephropathy. IGF-1Eb or IGF-1Ec improves renal function as evidenced by a modulation in serum albumin concentration and a reduction in urine volume and protein levels. IGF-1Eb or IGF-1Ec also reduces diabetic glomerulosclerosis.

A method of modulating topical inflammatory response is disclosed. The method generally includes the selective removal of certain proteins, e.g., one or more cytokines such as interleukin-1β (IL-1β) and/or interleukin-6 (IL-6), from a topical site without substantially altering the local concentrations of other proteins that may be present at or near the topical site. Other proteins that are present at or near the topical site can include serum albumin, fibrinogen, and immunoglobin G (IgG). Hydrogel compositions that can be used to practice the methods of the invention are provided. The invention further provides methods of preparing such hydrogel compositions.

New designed ankyrin repeat domains with binding specificity for serum albumin, recombinant binding proteins comprising at least two designed ankyrin repeat domains with binding specificity for serum albumin, as well as recombinant binding proteins comprising at least one designed ankyrin repeat domain with binding specificity for hepatocyte growth factor (HGF), at least one designed ankyrin repeat domain with binding specificity for vascular endothelial growth factor (VEGF-A), and at least two designed ankyrin repeat domain with binding specificity for serum albumin are described, as well as nucleic acids encoding such designed ankyrin repeat domains and recombinant binding proteins, pharmaceutical compositions comprising such designed ankyrin repeat domains, recombinant binding proteins or nucleic acids and the use of such designed ankyrin repeat domains, recombinant binding proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.

Methods and systems for increasing stability of a target polypeptide in a serum are described. The methods and systems utilize a fusion protein comprising a single-domain antibody against a serum albumin (SASA), the target polypeptide and optionally a linker. The fusion protein has a significantly prolonged serum half life in comparison with the target polypeptide alone. The SASA fusion tag also facilitates the expression and purification of the fusion protein. This allows direct in vivo screening or utilization of the target polypeptide for its biological activity or efficacy regardless of its intrinsic serum half life, which has significantly increased the number of candidates for the development of novel protein based diagnosis or treatment.

New designed repeat proteins with binding specificity for serum albumin are described, as well as nucleic acids encoding such serum albumin binding proteins, pharmaceutical compositions comprising such proteins, the use of such proteins to modify the pharmacokinetics of therapeutic relevant polypeptides and the use of such proteins in the treatment of diseases. The repeat proteins of the invention have a substantially increased half-life in plasma compared to proteins not binding serum albumin.

Antibodies that specifically bind to an epitope on the serum albumin, including human and/or mouse serum albumin are provided. Nucleic acids encoding such antibodies and cells capable of expressing such antibodies are also provided.

A non-serum culture medium for human epidermal cells is based on IMDM culture medium and features additional use of hydrogen peroxidase, bovin serum albumin, human transferrin, cholesterin, insulin, hydrocortisone, epidermal cell growth factor, ox hypophysis extract and ethanolamine. Its advantages are no interference and high correctness and precision. It can be used for medicine research and medical purpose.

A method for screening the active components of Chinese-medicinal material includes such steps as mixing the liquid extract of the Chinese-medicinal material to be screened with serum albumin solution, sampling by equilibrium dialysis or microdialysis to obtain reactive dialytic liquid, mixing the liquid extract of the Chinese-medicinal material to be screened with the blank solution not containing serum albumin, sampling by equilibrium dialysis or microdialysis to obtain blank dialytic liquid, respective efficient liquid-phase chromatography analysis for said reactive dialytic liquid and blank dialytic liquid, and calculating the albumin combining percentage of each component.

The VEGF slowly releasing injection microsphere support includes matrix, VEGF, protectant and ammonium bicarbonate. It features the matrix of polylactic acid-hydroxyl acetate copolymer of polylactic acid/hydroxyl acetate ratio 25:75 to 75:25; the protectant comprising zinc carbonate, serum albumin, mycose and mannitol; the weight ratio between VEGF and polylactic acid-hydroxyl acetate copolymer of 1:100000 to 1:10; and the microsphere size of 50-1000 microns. It is prepared through one W/O/W solvent volatilizing process or one fine medicine powder adding W/O/W solvent volatilizing process. The preparation process is simple, easy in operation and high in repeatability. In the microsphere support, protein medicine VEGF may be in vitro released for over 4 weeks in approached zero order kinetic mode. The present invention may be used in the repair and treatment of different kinds of tissue and blood vessel damage.

The present invention is one kind snake venom cytozyme hemostatic containing blood coagulating factor, activator RVV-X and synergist snake venom thrombase. Preferably, the snake venom cytozyme hemostatic contains also serum albumin, for example human serum albumin. In addition, the present invention also discloses the preparation process and hemostatic use of high purity RVV-X.

The invention relates to the technical field of cell culture, and in particular to a serum-free culture medium, a preparation method thereof and a culture method of mesenchymal stem cells. The culturemedium consists of the following components: non-essential amino acid, glutamine, hydrocortisone, dexamethasone, polyvinyl alcohol, recombinant human insulin, recombinant human transferrin, a recombinant human epidermal growth factor, a recombinant human basic fibroblast growth factor, a recombinant human Wnt-3a protein, a recombinant human fibronectin, recombinant human laminin, L-glutathione, L-ascorbic acid, beta-mercaptoethanol, ethanolamine, Pluronic F-68, Tween 80, cholesterol, adenine, sodium selenite and a basic culture medium. According to the invention, polyvinyl alcohol can replaceserum albumin in a serum-free culture medium in carrier function, so that proliferation capacity of mesenchymal stem cells is effectively improved. Polyvinyl alcohol has more stable performance thanserum albumin, and the problem that proliferation capacity and passage capacity of stem cells are reduced can be effectively solved.

A composition comprising a non-albumin protein is stabilised by the addition of a highly purified recombinant human serum albumin. The non-albumin protein may be Factor VIII.

The invention discloses freeze-dried powder for repairing acne marks and scars. The freeze-dried powder is prepared by the steps of: A, preparing raw materials; B, dissolving mannitol, oligopeptide-3, disodium hydrogen phosphate and oligopeptide-2 in water at normal temperature, placing the solution in a 121 DEG C autoclave, and performing sterilization at a constant temperature for 20 minutes to form a solution A; C, sequentially adding sodium dihydrogen phosphate and serum albumin into the solution A, shaking the mixture uniformly, and performing filtration by using a filter membrane to obtain a solution B; D, standing the solution B for 18-36h, and then performing filling; E, performing freeze drying on the solution B after filling; and F, packaging the product after drying. The freeze-dried powder prepared by the invention can achieve multiple repair and protection of a skin damaged by acnes, and can promote skin microcirculation and improve the acne marks to ensure that the skin can recovered to a healthy state.

The invention provides a kit for quantitatively detecting bovine milk serum albumin. The kit comprises a bovine serum albumin specific peptide, an isotope labeled bovine milk serum albumin specific peptide, an isotope labeled bovine serum albumin internal standard, a proteolytic reagent and a quality control sample. The amino acid sequence of the bovine serum albumin specific peptide is LVNELTEFAK; the amino acid sequence of the isotope labeled bovine milk serum albumin specific peptide is LV *NEL*TEFAK; and the amino acid sequence of the isotope labeled bovine serum albumin internal standard is QCPFDEHVKLV*NEL*TEFAKTCVADESHAGC, wherein V* and L* are carbon and nitrogen isotope labeled amino acids. The kit can accurately quantitatively detect the bovine milk serum albumin in various milk-containing products by adopting the isotope labeled internal standard synthesized through researches and designing, ensures the result reliability, and also has the advantages of less reagent consumption and low detection cost.

Compositions comprising non-naturally occurring serum albumin binding moieties are described, together with methods of use thereof, e.g., for detecting or isolating serum albumin molecules in a solution, for blood circulation imaging, and for linking therapeutics or other molecules to albumin. Preferred serum albumin binding peptides having a high affinity for human serum albumin are particularly disclosed.

The invention discloses a method for detecting clenbuterol residues, which comprises the following steps: (1) preparing, identifying and biotinylating clenbuterol-calf serum albumin conjugate; (2) coupling anti-clenbuterol monoclonal antibody on fluorescent microspheres; (3) drawing standard curve for suspension chip detection of clenbuterol residues; (4) testing specificity of suspension chip detection of clenbuterol residues; and (5) measuring the concentration of clenbuterol residues sample. The method of the invention for detecting clenbuterol residues has the advantages of simple operation, rapidness, sensitivity and low cost; and the overall detection process only takes 1-2h.

This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an Fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a WAP domain containing polypeptide or a sequence derived from a WAP containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules.